Logo

Thermo Fisher's Oncomine Dx Target Test Receives the US FDA's Approval as a CDx for the Treatment of IDH1-Mutated Cholangiocarcinoma

Share this

Thermo Fisher's Oncomine Dx Target Test Receives the US FDA's Approval as a CDx for the Treatment of IDH1-Mutated Cholangiocarcinoma

Shots:

  • The FDA has approved the Oncomine Dx target test as a CDx to identify patients with IDH1 mutated CCA who may be candidates for Servier’s Tibsovo
  • Oncomine Dx Target Test is NGS based CDx test that provides robust results in the IDH1 gene clinically associated with CCA & is currently approved in 15+ countries- including the US- EU- Japan- South Korea & Middle East. The test had received the 1st FDA's approval in 2017 & is now approved for 4 targeted therapies for NSCLC & 1 for CCA in the US
  • Thermo Fisher & Servier collaborated to develop & commercialize a CDx supporting Oncomine precision assay to identify LGG patients with IDH1 & 2 mutations who may be eligible for vorasidenib

| Ref: PR Newswire | Image: CPhl Online

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions